As of November 6, 2026, 20/20 Biolabs, Inc. is a publicly traded company (Nasdaq: AIDX). The largest holder reporting an active stake on Schedule 13D is Jonathan Cohen, the executive officer and a director, at 16.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Streeterville Capital LLC (9.9%), Full Succeed International Limited (6.3%) (Schedule 13D, March 10, 2026).
Is this your company?
About to sign with, pay or invest in 20/20 Biolabs, Inc.? See the free Snapshot first.
Free to see. No signup.
Is 20/20 Biolabs, Inc. a real, registered company?
- 20/20 Biolabs, Inc. files with the SEC under CIK 1139685 (its SEC filings).
- Its shares are listed under the ticker AIDX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Rockville, Maryland, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under 20/20 GeneSystems, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Full Succeed International Limited (filed 2026-03-10).
Who are 20/20 Biolabs, Inc.'s owners and officers?
20/20 Biolabs, Inc.: incorporated in Delaware; business address in Rockville, Maryland; industry Services-Testing Laboratories (S-1, 2026-04-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-02-26)
- : Executive Officer (Form D, 2025-02-26)
- : Executive Officer (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
- : Director (Form D, 2025-02-26)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-03-10 | Full Succeed International Limited | 6.3% |
| Schedule 13D, 2026-03-10 | Jonathan M Cohen | 16.8% |
| Schedule 13G, 2026-02-25 | Streeterville Capital LLC | 9.9% |
Questions about who owns 20/20 Biolabs, Inc.
Who owns 20/20 Biolabs, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of 20/20 Biolabs, Inc.: Jonathan M Cohen (16.8%, Schedule 13D, filed 2026-03-10), Streeterville Capital LLC (9.9%, Schedule 13G, filed 2026-02-25) and Full Succeed International Limited (6.3%, Schedule 13G, filed 2026-03-10).
Who are the largest shareholders of 20/20 Biolabs, Inc.?
By the share each holder's latest filing reports, the largest holders of 20/20 Biolabs, Inc. on this page are Jonathan M Cohen (16.8%), Streeterville Capital LLC (9.9%) and Full Succeed International Limited (6.3%).
When did Jonathan M Cohen buy into 20/20 Biolabs, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Jonathan M Cohen on this page is the Schedule 13D, filed 2026-03-10, reporting 16.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on 20/20 Biolabs, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on 20/20 Biolabs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 20/20 Biolabs, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own 20/20 Biolabs, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 1,366,400 shares (10.7% of shares outstanding) (Form 3, 2026-02-19).
- , a director: 30,275 shares (0.24% of shares outstanding) (Form 4, 2026-02-23).
- , a director: 14,335 shares (0.11% of shares outstanding) (Form 4, 2026-02-23).
- , a director: 7,700 shares (0.06% of shares outstanding) (Form 4, 2026-02-23).
- , a director: 31 shares (0.00% of shares outstanding) (Form 4, 2026-02-23).
Shares outstanding: 12,770,303 as of 2026-08-14, from the company's latest SEC cover page.
How much has 20/20 Biolabs, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-02-26 | $70K | $3M |
Latest IPO step: 20/20 Biolabs, Inc. filed to go public (S-1, 2026-04-06).
IPO filings: S-1, 2026-04-06, S-1/A, 2026-01-26, S-1/A, 2026-01-21, S-1, 2025-12-12; ticker AIDX on Nasdaq Capital Market.
Keep reading
More on 20/20 Biolabs, Inc. and the records around it.
20/20 Biolabs, Inc. elsewhere on the record
- IPO filing Apr 2026
- 5%+ stake filings Mar 2026
- Crowdfunding filing Dec 2025
Companies that share a holder
- Streeterville Capital LLC also filed stake reports on 29 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Vivos Therapeutics, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/20-20-biolabs